Back

Pomerantz investigates Emergent BioSolutions after 29.58% stock plunge

Verifying
  • Pomerantz LLP is investigating Emergent BioSolutions and certain officers or directors for alleged unlawful practices.
  • 29.58% was the Aug. 6 decline in Emergent shares, which closed at $5.31.
  • Emergent disclosed a $191.3 million NARCAN impairment charge in its Aug. 5 results.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.